Compare Becton Dickinson and Co (BDX) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs TJX Companies Inc — how do they compare? Becton Dickinson and Co trades at $181.69 (market cap $49.41B), while TJX Companies Inc trades at $153.54 (market cap $172.05B). The key difference: TJX Companies Inc is far larger — about 3.5× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| BDX | TJX | |
|---|---|---|
Market Cap | $49.41B | $172.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $168.41 |
52-Week Low | $138.62 | $132.62 |
Enterprise Value | $65.51B | $180.65B |
Dividend Yield | 2.32% | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $180.64, up 0.56% today, near its consensus price target of $183. The stock shows bullish technical signals with strong moving averages and recent earnings beats in Q2 2026. Revenue growth is steady, with Q3 2026 reaching $5 billion, though margins face pressure from tariffs. The company maintains a Dividend Aristocrat status with consistent payouts.
Outlook is cautiously optimistic with analyst consensus leaning buy, but risks include margin compression and debt levels. The stock offers stability through dividends and sector resilience, yet investors should monitor earnings sustainability and competitive threats in the medical technology space.
TJX trades at $154.17, down 2.92% over the past day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.19 exceeding the $1.02 estimate. Revenue grew to $56.36 billion in 2025, and net income margin improved to 8.63%. Analysts maintain a bullish consensus with an average price target of $181.80, citing momentum and value prospects.
The outlook for TJX remains positive driven by consistent earnings outperformance and robust profitability metrics like a 61.25% ROE. Key risks include competitive pressures in discount retail and sensitivity to consumer spending trends. The stock offers upside to analyst targets but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
